CKI 7 Dihydrochloride: Unraveling CK1 Signaling in Cancer and Circadian Biology

Introduction

Casein kinase 1 (CK1) is a serine/threonine protein kinase family at the crossroads of cell signaling, circadian rhythm regulation, and oncogenic processes. Recent advances in kinase inhibitor development have yielded precise tools for probing CK1-mediated phosphorylation, with CKI 7 dihydrochloride standing out as a highly selective, cell-permeable CK1 inhibitor for signaling pathway research. This article provides an in-depth exploration of CKI 7 dihydrochloride’s mechanism of action, its pivotal role in advanced cancer biology and circadian rhythm studies, and how it enables novel experimental strategies beyond conventional approaches. By integrating recent findings on phosphorylation-dependent regulation in cancer (see Luo et al., 2026), we highlight the translational potential of CK1 inhibition in disease modeling and therapeutic target discovery.

CKI 7 Dihydrochloride: Chemical and Biophysical Profile

CKI 7 dihydrochloride (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide dihydrochloride) is a synthetic, research-grade protein kinase inhibitor with a molecular weight of 358.67 and formula C₁₁H₁₂ClN₃O₂S·2HCl. Its high purity (98%) and solubility characteristics (<17.93 mg/ml in DMSO, <7.17 mg/ml in water) make it suitable for both biochemical and cell-based assays. Optimal storage at -20°C preserves stability, and long-term solution storage is not recommended. Available in a range of quantities (1mg, 5mg, 10mg, 25mg, 50mg), CKI 7 dihydrochloride supports diverse experimental designs, from high-throughput screening to precise mechanistic studies.

Mechanism of Action: ATP-Competitive Inhibition of CK1

CKI 7 dihydrochloride functions as an ATP-competitive kinase inhibitor, binding selectively to the ATP-binding site of CK1 isoforms. By blocking ATP access, it prevents the phosphorylation of serine/threonine residues on downstream targets, thereby modulating key signaling cascades. This protein phosphorylation inhibition is fundamental to dissecting the role of CK1 in Wnt/β-catenin signaling, circadian rhythm regulation, and DNA repair mechanisms.

Specificity and Selectivity

Unlike broad-spectrum kinase inhibitors, CKI 7 dihydrochloride offers exceptional selectivity for CK1, minimizing off-target effects and experimental confounders. This selectivity underpins its widespread use as a CK1 inhibitor for biochemical assays and CK1 inhibitor for cell-based assays, providing reproducible results in both in vitro and in vivo models.

CK1 Signaling Pathways: From Molecular Mechanisms to Disease Relevance

Wnt/β-Catenin Signaling Modulation

CK1-mediated phosphorylation is a pivotal event in the Wnt/β-catenin signaling pathway. CK1 phosphorylates β-catenin and other pathway components, influencing their stability, localization, and activity. Inhibition of CK1 by CKI 7 dihydrochloride disrupts this regulatory axis, allowing researchers to probe the consequences of altered Wnt signaling in cell fate determination, stem cell renewal, and oncogenic transformation. Recent literature, such as Luo et al. (2026), underscores the impact of phosphorylation-dependent mechanisms in cancer progression, highlighting the translational value of CK1 inhibitors in targeting aberrant signaling networks (Luo et al., 2026).

Circadian Rhythm Regulation Studies

The circadian clock relies on the precise timing of phosphorylation events mediated by CK1. Inhibition of CK1 activity with CKI 7 dihydrochloride enables detailed analysis of circadian period length, phase shifts, and the stability of core clock proteins. This has broad relevance for neurobiology research, sleep disorders, and metabolic diseases where circadian misregulation plays a pathogenic role.

Protein Phosphorylation and Apoptosis Assays

CKI 7 dihydrochloride facilitates apoptosis assays using CK1 inhibitors by modulating phosphorylation-dependent survival signals. In cancer biology research, this is instrumental for elucidating how CK1 influences cell cycle checkpoints, p53 activity, and apoptotic resistance. The compound’s cell permeability ensures effective inhibition in both monolayer cultures and complex 3D models.

Advanced Applications: Beyond Basic Signaling Studies

Cancer Biology Research with CK1 Inhibitors

CK1 has emerged as a key regulator of oncogenic signaling, cell adhesion, and metastasis. The study by Luo et al. (2026) revealed a phosphorylation-dependent ubiquitination pathway involving MAPK10 and keratin 16 (KRT16) in non-small cell lung cancer (NSCLC) metastasis. Although the study focused on MAPK10, it illustrates the broader principle that kinase-mediated phosphorylation can control protein stability and cancer cell behavior (Luo et al., 2026). CKI 7 dihydrochloride empowers researchers to dissect similar phosphorylation events within the CK1 axis, enabling the identification of novel biomarkers and therapeutic targets for cancer progression and metastasis.

Notably, while existing articles such as "CKI 7 dihydrochloride: Advanced Casein Kinase 1 Inhibitor…" focus on the compound’s application in modulating signaling pathways, our analysis delves deeper into the interplay between kinase inhibition and ubiquitin-mediated protein degradation—an emerging frontier in cancer therapeutics. By integrating phosphorylation and proteostasis, this article highlights a research direction not fully explored in prior content.

Neurobiology Research and Circadian Rhythm Disorders

Beyond oncology, CKI 7 dihydrochloride is a critical tool for investigating CK1’s role in neurobiology, particularly in synaptic plasticity, neurodegenerative diseases, and circadian regulation. Precise modulation of CK1 activity enables researchers to model neurodegenerative disease mechanisms and identify pharmacological interventions for disorders such as Alzheimer’s and Parkinson’s disease, where CK1-mediated phosphorylation of tau and other proteins is implicated.

Innovative Use in Cell Signaling Research

CKI 7 dihydrochloride’s robust selectivity and well-characterized solubility profile (notably, CK1 inhibitor solubility in DMSO) facilitate its use in high-content screening platforms and advanced phosphoproteomics. Its compatibility with both classical and emerging assay formats (e.g., time-resolved FRET, single-cell phospho-profiling) extends its utility for cell signaling research beyond traditional endpoints.

Comparative Analysis with Alternative Approaches

Alternative CK1 inhibitors and genetic manipulation (e.g., RNAi, CRISPR/Cas9) each offer distinct advantages and limitations. Small-molecule inhibitors like CKI 7 dihydrochloride provide rapid, reversible, and dose-dependent modulation of kinase activity, supporting temporal studies and rescue experiments. In contrast, genetic approaches can yield permanent knockdown but may trigger compensatory mechanisms or off-target effects.

Compared to other CK1 inhibitors, CKI 7 dihydrochloride offers a superior balance of selectivity, solubility, and experimental versatility. For instance, while "CKI 7 Dihydrochloride: Precision Tool for Casein Kinase 1…" emphasizes the compound’s solubility and specificity, our review uniquely focuses on the broader experimental implications and translational relevance of CK1 inhibition in disease modeling.

Practical Considerations: Dosage, Storage, and Handling

CKI 7 dihydrochloride is supplied in research-use-only quantities (1mg, 5mg, 10mg, 25mg, 50mg), meeting the needs of both pilot studies and large-scale screens. For optimal activity, reconstitute in DMSO to the desired concentration, ensuring that the final working concentration avoids precipitation. As with all protein kinase inhibitor compounds, storage at -20°C is recommended to preserve activity (CK1 inhibitor storage at -20°C), and repeated freeze-thaw cycles should be minimized.

Translational Relevance: From Bench to Biomarker Discovery

The integration of CK1 inhibition with advanced omics techniques enables the identification of phosphorylation-dependent biomarkers and therapeutic targets. For example, the MAPK10/KRT16/RNF213 axis described by Luo et al. (2026) demonstrates how kinase signaling mediates protein stability, tumor suppression, and prognosis in NSCLC. By applying CKI 7 dihydrochloride in similar systems, researchers can clarify the role of CK1 in protein ubiquitination, metastatic potential, and patient stratification.

CK1 in Cancer and Neurodegenerative Disease Models

CK1’s involvement in cancer signaling and neurodegenerative diseases positions CKI 7 dihydrochloride as a valuable research chemical for mechanistic and translational studies. Its use in combination with omics, imaging, and functional assays accelerates pathway mapping and target validation for drug discovery pipelines.

Conclusion and Future Outlook

CKI 7 dihydrochloride from APExBIO is more than a standard CK1 kinase inhibitor compound; it is a precision tool for dissecting the molecular logic of cell signaling networks. By enabling fine-tuned modulation of CK1 activity, this reagent supports breakthroughs in cancer biology research, circadian rhythm studies, and neurobiology research. Its unique utility lies not only in the inhibition of CK1-mediated phosphorylation but also in facilitating discovery at the intersection of signaling, proteostasis, and disease.

While prior works such as "CKI 7 dihydrochloride: Selective Casein Kinase 1 Inhibitor…" provide practical guidance on experimental integration, this article advances the field by connecting CK1 inhibition to emerging paradigms in ubiquitin-mediated protein turnover and biomarker discovery. As research moves towards systems-level understanding, CKI 7 dihydrochloride will remain an indispensable asset for scientific innovation.

For detailed product specifications and ordering information, visit the official CKI 7 dihydrochloride page at APExBIO.